Stonepine Capital Takes 5.1% Stake in CalciMedica

TL;DR

**Stonepine Capital just bought 5.1% of CalciMedica, signaling institutional confidence.**

AI Summary

Stonepine Capital Management, LLC, a Delaware-incorporated investment firm, has disclosed a significant stake in CalciMedica, Inc. (NASDAQ: CALC), a pharmaceutical preparations company. As of January 22, 2024, Stonepine Capital Management, LLC reported beneficial ownership of 1,000,000 shares of CalciMedica's Common Stock, representing 5.1% of the company's outstanding shares. This matters to investors because a substantial investment by an institutional fund like Stonepine Capital Management can signal confidence in CalciMedica's future prospects, potentially attracting more investor interest and influencing stock price.

Why It Matters

This filing indicates a notable institutional investor, Stonepine Capital Management, sees value in CalciMedica, which could be a positive signal for other investors.

Risk Assessment

Risk Level: low — This filing indicates an institutional investment, which is generally seen as a positive or neutral event, not increasing risk.

Analyst Insight

A smart investor would research Stonepine Capital Management's investment thesis and CalciMedica's recent developments to understand the potential drivers behind this significant stake, considering it a positive signal.

Key Numbers

• 1,000,000 — Shares Beneficially Owned (Represents the total number of shares Stonepine Capital Management, LLC holds in CalciMedica, Inc.)
• 5.1% — Percentage of Class (Indicates the proportion of CalciMedica's outstanding common stock owned by Stonepine Capital Management, LLC.)

Key Players & Entities

• Stonepine Capital Management, LLC (company) — reporting person, institutional investor
• CalciMedica, Inc. (company) — subject company, pharmaceutical preparations
• 1,000,000 (dollar_amount) — shares beneficially owned
• 5.1% (dollar_amount) — percentage of class beneficially owned
• January 22, 2024 (person) — date of event requiring filing

Forward-Looking Statements

• CalciMedica's stock price may see increased attention due to institutional interest. (CalciMedica, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

• calc13g.htm (SC 13G) — 57KB
• 0000935836-24-000078.txt ( ) — 59KB

Ownership

Item 4. Ownership. See Items 5-9 and 11 of the cover page for each Filer. The shares of Common Stock beneficially owned by the Filers reported in this Schedule 13G consist of (1) 522,602 shares of Common Stock held by the Filers, (2) Tranche A Warrants to acquire 261,301 shares of Common Stock, and (3) Tranche B Warrants to purchase 261,301 shares of Common Stock. The Trance A Warrants and Tranche B Warrants are Stock outstanding as of January 25, 2024.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Material to Be Filed as Exhibits

Item 10. Material to Be Filed as Exhibits Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

Certification of the General Partner, Mr. Plexico and Mr. Lynch

Item 11. Certification of the General Partner, Mr. Plexico and Mr. Lynch By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Certification of the Partnership By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 7 CUSIP No. 38942Q202 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated:January 31, 2024 STONEPINE CAPITAL MANAGEMENT, LLC By: /s/ Timothy P. Lynch Timothy P. Lynch Managing Member STONEPINE CAPITAL, L.P. By:Stonepine Capital Management, LLC, General Partner By: /s/ Timothy P. Lynch Timothy P. Lynch Managing Member /s/ Jon M. Plexico Jon M. Plexico /s/ Timothy P. Lynch Timothy P. Lynch 8 CUSIP No. 38942Q202 EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section

View Full Filing

View this SC 13G filing on SEC EDGAR